All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

perphenazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	2113	58-39-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: perphenazine perfenazine perfenil perphenan perphenazin thilatazin tranquisan perphanzine	An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE. Molecular weight: 403.97 Formula: C21H26ClN3OS CLOGP: 4.01 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 29.95 ALOGS: -4.23 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O
7	mg	P
10	mg	P
16	mg	R

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.99 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	40 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	18 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	27 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.07 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	9.40 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.02 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.459		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.918		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	25.645	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	41.400	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	2.290	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	4.520	%	High	1
herg	hERG pIC50	5.930	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	28.907	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	58.614	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	1.610	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK	48
kinase-selectivity-class	AXL,EPHB4,PDK4,SIK2	4
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	3.776		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	162.181		High	1
mppb	Mouse plasma protein binding (% unbound)	2.550		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	9.376		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	7.490	%	High	1
rh-clint	Rat hepatocyte intrinsic clearance	254.097	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	14.920	%	High	1
rppb	Rat plasma protein binding (% unbound)	1.970	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	52.723	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Feb. 27, 1957	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tardive dyskinesia	303.24	29.18	76	4280	10854	90613237
Dystonia	252.63	29.18	72	4284	16747	90607344
Parkinsonism	232.94	29.18	65	4291	14000	90610091
Dyskinesia	186.58	29.18	69	4287	36465	90587626
Myoclonus	167.08	29.18	54	4302	19114	90604977
Apraxia	155.84	29.18	33	4323	2229	90621862
Creatinine renal clearance increased	143.62	29.18	33	4323	3248	90620843
Renal function test abnormal	141.11	29.18	38	4318	7153	90616938
Drug abuse	135.56	29.18	70	4286	82277	90541814
Head titubation	125.55	29.18	25	4331	1243	90622848
Sedation complication	116.76	29.18	40	4316	16904	90607187
Creatinine renal clearance decreased	104.95	29.18	38	4318	18861	90605230
Multiple drug therapy	91.78	29.18	27	4329	6982	90617109
Sedation	91.05	29.18	45	4311	48126	90575965
Blood calcium decreased	87.70	29.18	38	4318	30144	90593947
Polydipsia	86.01	29.18	23	4333	4208	90619883
Orthostatic hypotension	81.80	29.18	40	4316	41787	90582304
Depressed level of consciousness	81.44	29.18	48	4308	72736	90551355
Blood magnesium increased	81.14	29.18	21	4335	3387	90620704
Pleural fibrosis	80.02	29.18	21	4335	3575	90620516
Presbyacusis	78.56	29.18	20	4336	3022	90621069
Overdose	78.34	29.18	63	4293	157646	90466445
Pleural thickening	77.26	29.18	20	4336	3228	90620863
Neuroleptic malignant syndrome	71.45	29.18	27	4329	15069	90609022
Hyperprolactinaemia	71.44	29.18	21	4335	5412	90618679
Movement disorder	66.63	29.18	31	4325	28988	90595103
Toxicity to various agents	66.04	29.18	75	4281	287771	90336320
Extrapyramidal disorder	65.91	29.18	26	4330	16277	90607814
Cognitive disorder	62.86	29.18	40	4316	69367	90554724
Deafness neurosensory	62.53	29.18	20	4336	6821	90617270
Drug interaction	61.66	29.18	71	4285	276382	90347709
Epigastric discomfort	60.55	29.18	20	4336	7548	90616543
Sopor	58.68	29.18	27	4329	24617	90599474
Balance disorder	48.61	29.18	39	4317	97041	90527050
Cyst	48.57	29.18	21	4335	16540	90607551
Blood potassium increased	44.04	29.18	21	4335	20728	90603363
Tremor	43.99	29.18	45	4311	153128	90470963
Mitochondrial encephalomyopathy	43.66	29.18	7	4349	98	90623993
Ileus paralytic	42.94	29.18	14	4342	5071	90619020
Osteopenia	41.98	29.18	21	4335	22981	90601110
Bone cyst	34.84	29.18	10	4346	2368	90621723
Hyponatraemia	34.34	29.18	37	4319	133501	90490590
Deformity	34.27	29.18	15	4341	12155	90611936
Osteosclerosis	32.89	29.18	11	4345	4309	90619782
Moaning	32.64	29.18	8	4348	1035	90623056
Hypotension	32.55	29.18	57	4299	325340	90298751
Skin lesion	32.48	29.18	21	4335	37344	90586747
Mobility decreased	30.54	29.18	48	4308	250686	90373405
Onychophagia	30.50	29.18	5	4351	81	90624010
Bladder disorder	29.44	29.18	13	4343	10759	90613332
Intentional self-injury	29.29	29.18	18	4338	29316	90594775

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Antipsychotic drug level below therapeutic	581.27	47.07	114	3356	3090	42614775
Akathisia	567.85	47.07	138	3332	10313	42607552
Therapeutic product effect variable	560.19	47.07	110	3360	2999	42614866
Disinhibition	559.06	47.07	114	3356	3781	42614084
Obsessive-compulsive disorder	539.95	47.07	122	3348	6621	42611244
Euphoric mood	512.55	47.07	116	3354	6337	42611528
Increased appetite	465.17	47.07	114	3356	8792	42609073
Suicide attempt	329.77	47.07	128	3342	45972	42571893
Leukaemia	261.45	47.07	66	3404	5706	42612159
Therapeutic product effect incomplete	224.50	47.07	111	3359	70828	42547037
Weight increased	212.22	47.07	123	3347	107860	42510005
Dyslipidaemia	211.66	47.07	62	3408	9356	42608509
Leukopenia	210.23	47.07	108	3362	74638	42543227
Toxicity to various agents	196.73	47.07	156	3314	228980	42388885
Obesity	173.77	47.07	61	3409	16398	42601467
Prescribed overdose	160.10	47.07	54	3416	12873	42604992
Schizoaffective disorder	116.82	47.07	28	3442	1942	42615923
Irritability	91.57	47.07	45	3425	28083	42589782
Neuroleptic malignant syndrome	77.87	47.07	37	3433	21435	42596430
Drug ineffective	75.03	47.07	160	3310	630037	41987828
Product use in unapproved indication	50.13	47.07	68	3402	184388	42433477
Hypertension	47.49	47.07	63	3407	167141	42450724

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Akathisia	226.74	30.71	69	6186	17044	110566000
Tardive dyskinesia	224.59	30.71	65	6190	13514	110569530
Antipsychotic drug level below therapeutic	200.64	30.71	40	6215	1695	110581349
Therapeutic product effect variable	188.32	30.71	41	6214	2677	110580367
Disinhibition	177.07	30.71	40	6215	3094	110579950
Dystonia	168.44	30.71	61	6194	25744	110557300
Parkinsonism	165.85	30.71	58	6197	22129	110560915
Obsessive-compulsive disorder	153.02	30.71	42	6213	7199	110575845
Euphoric mood	144.79	30.71	42	6213	8785	110574259
Creatinine renal clearance increased	134.97	30.71	33	6222	3592	110579452
Toxicity to various agents	134.62	30.71	150	6105	480405	110102639
Neuroleptic malignant syndrome	131.50	30.71	55	6200	34004	110549040
Dyskinesia	130.85	30.71	62	6193	51384	110531660
Renal function test abnormal	126.73	30.71	38	6217	8908	110574136
Apraxia	125.59	30.71	31	6224	3509	110579535
Head titubation	125.59	30.71	26	6229	1331	110581713
Dyslipidaemia	120.31	30.71	42	6213	15923	110567121
Increased appetite	115.16	30.71	40	6215	14937	110568107
Schizoaffective disorder	108.92	30.71	27	6228	3109	110579935
Sedation complication	107.75	30.71	41	6214	19814	110563230
Sedation	96.77	30.71	56	6199	69627	110513417
Creatinine renal clearance decreased	93.59	30.71	38	6217	21777	110561267
Hyperprolactinaemia	93.43	30.71	28	6227	6547	110576497
Drug abuse	88.26	30.71	76	6179	177335	110405709
Myoclonus	87.66	30.71	41	6214	32957	110550087
Blood calcium decreased	84.43	30.71	41	6214	35804	110547240
Multiple drug therapy	83.86	30.71	27	6228	7987	110575057
Irritability	78.79	30.71	43	6212	47766	110535278
Presbyacusis	76.83	30.71	20	6235	2799	110580245
Suicide attempt	76.57	30.71	56	6199	103338	110479706
Blood magnesium increased	75.35	30.71	21	6234	3802	110579242
Pleural thickening	73.12	30.71	20	6235	3379	110579665
Extrapyramidal disorder	70.94	30.71	34	6221	28833	110554211
Orthostatic hypotension	70.74	30.71	45	6210	66204	110516840
Polydipsia	68.75	30.71	23	6232	7665	110575379
Pleural fibrosis	68.43	30.71	20	6235	4288	110578756
Completed suicide	68.18	30.71	76	6179	242305	110340739
Leukaemia	65.28	30.71	22	6233	7496	110575548
Overdose	56.82	30.71	68	6187	233726	110349318
Depressed level of consciousness	55.58	30.71	48	6207	112230	110470814
Movement disorder	55.19	30.71	31	6224	36373	110546671
Epigastric discomfort	53.93	30.71	20	6235	8995	110574049
Drug interaction	53.70	30.71	99	6156	500084	110082960
Cognitive disorder	52.87	30.71	42	6213	87469	110495575
Deafness neurosensory	52.66	30.71	20	6235	9599	110573445
Enuresis	52.01	30.71	16	6239	4080	110578964
Ileus paralytic	48.80	30.71	20	6235	11717	110571327
Product use in unapproved indication	48.56	30.71	89	6166	447288	110135756
Obesity	47.28	30.71	44	6211	113307	110469737
Sopor	47.09	30.71	28	6227	36518	110546526
Cyst	45.36	30.71	21	6234	16475	110566569
Prescribed overdose	44.47	30.71	38	6217	87543	110495501
Balance disorder	42.47	30.71	42	6213	116518	110466526
Leukopenia	42.38	30.71	47	6208	148744	110434300
Mitochondrial encephalomyopathy	41.70	30.71	7	6248	111	110582933
Intentional self-injury	41.37	30.71	26	6229	37403	110545641
Tremor	39.84	30.71	53	6202	202179	110380865
Osteopenia	36.64	30.71	20	6235	22189	110560855
Weight increased	32.95	30.71	73	6182	419571	110163473
Muscle rigidity	32.50	30.71	19	6236	24012	110559032
Salivary hypersecretion	32.42	30.71	17	6238	17404	110565640
Blood potassium increased	31.58	30.71	21	6234	33228	110549816
Deformity	31.29	30.71	14	6241	10146	110572898
Constipation	31.25	30.71	65	6190	357721	110225323

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AB03	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperazine structure
FDA CS	M0016525	Phenothiazines
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018492	Dopamine Antagonists
FDA EPC	N0000175746	Phenothiazine
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:37930	phenothiazine antipsychotic drug
CHEBI has role	CHEBI:48561	dopaminergic antagonist
CHEBI has role	CHEBI:50919	antiemetic

Related Drugs by ATC class:

N05AB Phenothiazines with piperazine structure 9 drugs

acetophenazinebutaperazinedixyrazinefluphenazineperazineprochlorperazinethiopropazatethioproperazinetrifluoperazine

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Nausea and vomiting	indication	16932000
Schizophrenia	indication	58214004	DOID:5419
Mixed anxiety and depressive disorder	indication	231504006
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Organophosphate poisoning	contraindication	8260003
Weight gain finding	contraindication	8943002
Sinus tachycardia	contraindication	11092001
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Chronic disease of respiratory system	contraindication	17097001
Myocardial infarction	contraindication	22298006	DOID:5844
Glaucoma	contraindication	23986001	DOID:1686
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Parkinsonism	contraindication	32798002
Hyperthyroidism	contraindication	34486009	DOID:7998
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Paralytic ileus	contraindication	55525008	DOID:8442
Extrapyramidal disease	contraindication	76349003
Hyperglycemia	contraindication	80394007	DOID:4195
Chronic idiopathic constipation	contraindication	82934008
Open-angle glaucoma	contraindication	84494001	DOID:1067
Epilepsy	contraindication	84757009	DOID:1826
Leukopenia	contraindication	84828003	DOID:615
Stupor	contraindication	89458003
Tardive dyskinesia	contraindication	102449007
Prolonged QT interval	contraindication	111975006
Acute disease of cardiovascular system	contraindication	128487001
Bipolar affective disorder, current episode manic	contraindication	191618007
Angina pectoris	contraindication	194828000
Disease of liver	contraindication	235856003	DOID:409
Metabolic syndrome X	contraindication	237602007	DOID:14221
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Syncope	contraindication	271594007
Anemia	contraindication	271737000	DOID:2355
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Neutropenic disorder	contraindication	303011007	DOID:1227
Coma	contraindication	371632003
At risk for aspiration	contraindication	371736008
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Visual impairment	contraindication	397540003
Breastfeeding (mother)	contraindication	413712001
Myocardial ischemia	contraindication	414795007	DOID:3393
Obesity	contraindication	414916001	DOID:9970
Myocardial infarction in recovery phase	contraindication	418044006
Congenital long QT syndrome	contraindication	442917000
Carcinoma of female breast	contraindication	447782002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.21	Basic
pKa2	4.21	Basic
pKa3	2.21	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	9.32		WOMBAT-PK	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.19		WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		Ki	5.46		DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.07		WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	8.25		WOMBAT-PK
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.88		WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.55		WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	7.64		WOMBAT-PK
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8		WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.98		WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	9.52		WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.09		WOMBAT-PK
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.73		PDSP
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	7.48		WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.07		WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7.59		WOMBAT-PK
Retinal dehydrogenase 1	Enzyme	P00352	AL1A1_HUMAN		IC50	6.28		CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT	ANTAGONIST	Ki	7.60		IUPHAR
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	7.80		IUPHAR
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	5.85		CHEMBL

External reference:

ID	Source
4017939	VUID
N0000146289	NUI
D00503	KEGG_DRUG
4017939	VANDF
C0031184	UMLSCUI
CHEBI:8028	CHEBI
CHEMBL567	ChEMBL_ID
D010546	MESH_DESCRIPTOR_UI
DB00850	DRUGBANK_ID
4748	PUBCHEM_CID
209	IUPHAR_LIGAND_ID
637	INN_ID
FTA7XXY4EZ	UNII
8076	RXNORM
2271	MMSL
5261	MMSL
d00855	MMSL
001477	NDDF
387229007	SNOMEDCT_US
41147003	SNOMEDCT_US
FTA7XXY4EZ	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0042	TABLET, FILM COATED	4 mg	ORAL	ANDA	19 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0073	TABLET, FILM COATED	4 mg	ORAL	ANDA	19 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0330	TABLET, FILM COATED	2 mg	ORAL	ANDA	19 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0442	TABLET, FILM COATED	2 mg	ORAL	ANDA	19 sections
Perphenazine and Amitriptyline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-0574	TABLET, FILM COATED	4 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4101	TABLET, FILM COATED	2 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4102	TABLET, FILM COATED	4 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4103	TABLET, FILM COATED	8 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-4104	TABLET, FILM COATED	16 mg	ORAL	ANDA	20 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5060	TABLET, FILM COATED	2 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5061	TABLET, FILM COATED	4 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5062	TABLET, FILM COATED	8 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0603-5063	TABLET, FILM COATED	16 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8046	TABLET, FILM COATED	2 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8047	TABLET, FILM COATED	4 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8048	TABLET, FILM COATED	8 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0781-8049	TABLET, FILM COATED	16 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6599	TABLET, FILM COATED	2 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6600	TABLET, FILM COATED	4 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6601	TABLET, FILM COATED	8 mg	ORAL	ANDA	19 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	21695-141	TABLET, FILM COATED	4 mg	ORAL	ANDA	18 sections
Perphenazine	HUMAN PRESCRIPTION DRUG LABEL	1	21695-415	TABLET, FILM COATED	8 mg	ORAL	ANDA	18 sections
PERPHENAZINE	Human Prescription Drug Label	1	23155-799	TABLET	2 mg	ORAL	ANDA	16 sections
PERPHENAZINE	Human Prescription Drug Label	1	23155-800	TABLET	4 mg	ORAL	ANDA	16 sections
PERPHENAZINE	Human Prescription Drug Label	1	23155-801	TABLET	8 mg	ORAL	ANDA	16 sections
PERPHENAZINE	Human Prescription Drug Label	1	23155-802	TABLET	16 mg	ORAL	ANDA	16 sections
Perphenazine	Human Prescription Drug Label	1	33342-448	TABLET	2 mg	ORAL	ANDA	14 sections
Perphenazine	Human Prescription Drug Label	1	33342-449	TABLET	4 mg	ORAL	ANDA	14 sections
Perphenazine	Human Prescription Drug Label	1	33342-450	TABLET	8 mg	ORAL	ANDA	14 sections
Perphenazine	Human Prescription Drug Label	1	33342-451	TABLET	16 mg	ORAL	ANDA	14 sections